RED CELL THERAPEUTICS - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 87287791
Serial Number
87287791
Registration Number
6035628
Word Mark
RED CELL THERAPEUTICS
Status
700 - Registered
Status Date
2020-04-14
Filing Date
2017-01-03
Registration Number
6035628
Registration Date
2020-04-14
Mark Drawing
4000 - Standard character mark Typeset
Attorney Name
Christina M. Licursi, Esq.
Law Office Assigned Location Code
L50
Employee Name
VALLILLO, MELISSA C
Statements
Disclaimer with Predetermined Text
"CELL"
Goods and Services
Cells for medical and scientific research, engineered cells for medical and scientific research
Goods and Services
Cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations of engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; none of the foregoing used as vitamin-mineral supplements or for animals
Goods and Services
Technology for enabling the engineering and production of cells and cell therapeutics, namely, a platform for the modification and differentiation of cells and the expansion of cell populations
Goods and Services
Scientific research, pharmaceutical research, medical research; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2017-01-12
Primary Code
042
First Use Anywhere Date
2015-12-09
First Use In Commerce Date
2015-12-09
Current Trademark Owners
Party Name
Rubius Therapeutics, Inc.
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Rubius Therapeutics, Inc.
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Rubius Therapeutics, Inc.
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
CHRISTINA M. LICURSI, ESQ.
Address
Please log in with your Justia account to see this address.
Madrid International Filings
Entry Number
1
Reference Number
A0068166
Original Filing Date USPTO
2017-06-30
International Registration Number
1362379
International Registration Date
2017-06-30
International Status Code
480
International Renewal Date
2027-06-30
Madrid History Events
DateCodeDescription
2019-02-08PEXNXSUBSEQUENT DESIGNATION PROCESSED BY IB
2020-08-20CBMPPCEASING OF EFFECT PROCESSED
2020-08-20CBPSPPARTIAL CEASING OF EFFECT NOTICE SENT TO IB
2019-01-08SDRCVSUBSEQUENT DESIGNATION RECEIVED
2019-01-08SDSNTSUBSEQUENT DESIGNATION SENT TO IB
2017-06-30NEWAPNEW APPLICATION FOR IR RECEIVED
2017-07-01MCERTMANUALLY CERTIFIED
2017-07-01APPSTIR CERTIFIED AND SENT TO IB
2018-06-22ADDCHCHANGE OF ADDRESS RECEIVED FROM IB
2019-04-04ADDCHCHANGE OF ADDRESS RECEIVED FROM IB
2020-10-02PCBNPPARTIAL CEASING OF EFFECT PROCESSED BY IB
2017-08-24CREATAPPLICATION FOR IR REGISTERED BY IB
2020-07-14CBPCPPARTIAL CEASING OF EFFECT TO BE PROCESSED
Trademark Events
Event DateEvent Description
2017-01-12NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2017-03-28ASSIGNED TO EXAMINER
2017-04-04NON-FINAL ACTION WRITTEN
2017-04-04NON-FINAL ACTION E-MAILED
2017-04-04NOTIFICATION OF NON-FINAL ACTION E-MAILED
2017-10-04TEAS RESPONSE TO OFFICE ACTION RECEIVED
2017-10-18ASSIGNED TO LIE
2017-10-25CORRESPONDENCE RECEIVED IN LAW OFFICE
2017-10-25TEAS/EMAIL CORRESPONDENCE ENTERED
2018-01-13FINAL REFUSAL WRITTEN
2018-01-13FINAL REFUSAL E-MAILED
2018-01-13NOTIFICATION OF FINAL REFUSAL EMAILED
2018-05-02TEAS CHANGE OF OWNER ADDRESS RECEIVED
2018-05-02APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2018-07-02NON-FINAL ACTION WRITTEN
2018-07-02NON-FINAL ACTION E-MAILED
2018-07-02NOTIFICATION OF NON-FINAL ACTION E-MAILED
2019-01-02TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-01-04CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-01-04TEAS/EMAIL CORRESPONDENCE ENTERED
2019-01-02TEAS AMENDMENT OF USE RECEIVED
2019-01-08USE AMENDMENT FILED
2019-01-08AMENDMENT TO USE PROCESSING COMPLETE
2019-02-06TEAS CHANGE OF OWNER ADDRESS RECEIVED
2019-02-06APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2019-02-11USE AMENDMENT ACCEPTED
2019-02-11NON-FINAL ACTION WRITTEN
2019-02-11NON-FINAL ACTION E-MAILED
2019-02-11NOTIFICATION OF NON-FINAL ACTION E-MAILED
2019-02-12NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
2019-08-02TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-08-02CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-08-03TEAS/EMAIL CORRESPONDENCE ENTERED
2019-08-23SUBSEQUENT FINAL REFUSAL WRITTEN
2019-08-23SUBSEQUENT FINAL EMAILED
2019-08-23NOTIFICATION OF SUBSEQUENT FINAL EMAILED
2020-03-05EXAMINERS AMENDMENT -WRITTEN
2020-03-05EXAMINERS AMENDMENT E-MAILED
2020-03-05NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2020-03-05EXAMINER'S AMENDMENT ENTERED
2020-03-05APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
2020-03-10LAW OFFICE PUBLICATION REVIEW COMPLETED
2020-04-14REGISTERED-SUPPLEMENTAL REGISTER